CoChat

A Double-Masked, Placebo-Controlled Study of Fluoxetine for Hypochondriasis

Open access
Fallon, Brian A., Petkova, Eva, Skritskaya, Natalia, Sanchez-Lacay, Arturo, Schneier, Franklin, Vermes, Donna, Cheng, Jianfeng, Liebowitz, Michael R. · 2008 · Journal of Clinical Psychopharmacology

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

This study assessed the efficacy, durability, and tolerability of fluoxetine for hypochondriasis, a disorder for which controlled pharmacological trials are scarce. Fifty-seven patients with hypochondriasis were enrolled: 12 discontinued during the placebo run-in, and 45 were randomized to either fluoxetine or placebo for 12 weeks (acute treatment). Responder status was defined as a Clinical Global Impression rating for hypochondriasis of much or very much improved. Secondary outcome measures included severity of hypochondriasis, somatization, anxiety, and depression. Responders to acute treatment entered a 12-week maintenance phase to week 24. Sustained responders at week 24 entered a 12-week double-masked discontinuation phase. Primary analysis used the intent-to-treat sample. More patients responded with improvement in hypochondriasis when given fluoxetine compared with placebo, starting at week 8 (50.0% vs 19.0%, P = 0.03) and continuing to week 12 (62.5% vs 33.3%, P = 0.05). Mean dose at week 12 dose was 51.4 mg (SD, +/-23 mg). The acute treatment response was maintained to week 24 with more responders in the fluoxetine compared with the placebo group (54.2% vs 23.8%, P = 0.04). Significant improvement was not noted on the continuous secondary outcomes measures of hypochondriasis, with the exception of the Clinical Global Impression hypochondriasis severity scale at week 24. Likelihood of response was not associated with severity of psychiatric comorbidity. Durability of response after controlled drug discontinuation could not be reasonably assessed, given the small sample size of patients who entered the discontinuation phase (n = 10). Fluoxetine was well tolerated, with no significant differences in discontinuation due to side effects between treatment groups. Fluoxetine is a moderately effective and well-tolerated treatment for hypochondriasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e31818d21cf

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 11. Fallon BA. Pharmacologic strategies for hypochondriasis. In: Starcevic V, Lipsitt DR, eds. Hypochondriasis: Modern Perspectives on an Ancient Malady . New York, NY: Oxford University Press; 2001:329-351.

Cited by

See all 65

Metadata

Authors
Fallon, B. A., Petkova, E., Skritskaya, N., Sanchez-Lacay, A., Schneier, F., Vermes, D., Cheng, J., & Liebowitz, M. R.
Affiliations
New York State Psychiatric Institute (US)
Corresponding author
  • Fallon, Brian A.
  • Skritskaya, Natalia
  • Schneier, Franklin
  • Vermes, Donna
  • Liebowitz, Michael R.
Venue
Journal of Clinical Psychopharmacology
Published
2008-12
Volume
28
Issue
6
Pages
638-645
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2026930104
Cited by
63
References
20
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 3 · 2015: 5 · 2014: 7 · 2013: 5 · 2012: 4
FWCI
2.80
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Columbia Academic Commons (Columbia University)
Funders
  • Bristol-Myers Squibb
  • Pfizer
  • GlaxoSmithKline
  • National Institute of Mental Health (R29MH049409, R29 MH49409)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
  • Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
Keywords
fluoxetine, health anxiety, somatic symptom disorder, SSRI antidepressants, treatment efficacy, maintenance therapy, drug discontinuation, somatization, anxiety, depression, psychiatric comorbidity, tolerability
MeSH terms
Adult, Aged, Connecticut, Dose-Response Relationship, Drug, Double-Blind Method, Female, Fluoxetine, Humans, Hypochondriasis, Male, Middle Aged, New York, Patient Dropouts, Psychiatric Status Rating Scales, Severity of Illness Index, Time Factors, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.